EXPLORATION OF THE WEIGHT NEUTRAL EFFECTS OF INSULIN DETEMIR COMPARED TO INSULIN

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究正在研究胰岛素是否以及如何影响1型糖尿病患者的体重和饮食习惯。 接受胰岛素治疗的糖尿病患者往往体重增加，这可能会阻止他们坚持接受胰岛素治疗。地替米尔是美国食品和药物管理局批准用于糖尿病患者的一种长效胰岛素。它与其他长效胰岛素[NPH，甘精]相似，只是与其他类型的胰岛素相比，它与体重增加较少有关。造成这种情况的原因仍不清楚。一种可能性是，地特胰岛素在影响糖尿病患者进餐方式方面与其他胰岛素的作用不同。这项研究的目的是确定一餐中的食欲和卡路里是否受到用于治疗糖尿病的胰岛素类型的影响。这是一项初步研究，这意味着我们正在收集初步信息，以确定是否可以进行更大规模的研究。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This research is examining if and how insulin affects weight and eating habits in people with type 1 diabetes. Patients with diabetes treated with insulin often gain weight, which may deter them from adhering to insulin treatment. Detemir is one type of long acting insulin approved by the Food and Drug Administration for use in people with diabetes. It is similar to other long acting insulins [NPH, glargine] except that it has been associated with less weight gain compared to other types of insulin. The reasons for this are still unclear. One possibility is that detemir insulin acts differently than do other insulins in affecting how diabetic patients eat meals. The purpose of this study is to determine whether appetite and calories eaten during a meal are affected by the type of insulin used to treat diabetes. This is a pilot study which means we are gathering preliminary information to determine if a larger study can be done.